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Dedicated to my mother, Ivonne de Villiers 
 
who always encouraged and supported my academic interests, teaching me 
the value of science and learning from a young age.  “The only way we will 
understand the world is by asking questions and then trying to answer them.”  
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Abstract 
 
Background. Little is known about the current clinical profile and outcomes of patients with 
infective endocarditis (IE) in South Africa. 
   
Methods. We conducted a retrospective review of the records of patients admitted to 
Groote Schuur Hospital between 2009 and 2016 fulfilling universal criteria for definite or 
possible IE, in search of demographic, clinical, microbiological, echocardiographic, treatment 
and outcome information. 
 
Results. 105 patients fulfilled the modified Duke criteria for IE. The median age of the 
cohort was 39 years (IQR 29–51), with a male preponderance (61.9%). The majority of 
patients (72.4%) had left-sided native valve endocarditis, 14% had right-sided disease, and 
13.3% had prosthetic valve endocarditis. A third of the cohort had rheumatic heart disease. 
Although 41.1% of patients with left-sided disease had negative blood cultures, the three 
most common organisms cultured in this subgroup were Staphylococcus aureus (18.9%), 
Streptococcus spp. (16.7%) and Enterococcus spp. (6.7%). Participants with right-sided 
endocarditis were younger (29 years (IQR 27-37)), were predominantly intravenous drug 
users (IVDU; 73.3%) and the majority cultured positive for S. aureus (73.3%) with frequent 
septic pulmonary complications (40.0%). The overall in-hospital mortality was 16.2%, with 
no deaths in the group with right-sided endocarditis. Predictors of death in our patients 
were heart failure (OR 8.16, CI 1.77-37.70; p=0.007) and an age > 45 years (OR 4.73, CI 1.11-
20.14; p=0.036). Valve surgery was associated with a reduction in mortality (OR 0.09, CI 
0.02-0.43; p=0.003). 
 
Conclusions.  Infective endocarditis in a typical teaching tertiary care centre in South Africa 
remains an important clinical problem. In this setting, it continues to affect mainly young 
people with post-inflammatory valve disease and congenital heart disease. IE is associated 
with an in-hospital mortality that remains high. Intravenous drug-associated endocarditis 
caused by S. aureus is an important IE subset, comprising approximately 10% of all cases, a 
fact which was not reported 15 years ago, and culture-negative endocarditis remains highly 
prevalent. Heart failure in IE carries significant risk of death and needs a more intensive 
level of care in hospital. Finally, cardiac surgery was associated with reduced mortality, with 
the largest impact in those patients with heart failure.  
  
 5 
Acknowledgements 
 
I would like to acknowledge the following persons for their contribution to this dissertation: 
 
Ms. Imelda Booysen, Groote Schuur Hospital records department, for her support in 
accessing folders and providing a work space for data collection. 
 
Dr. Nicholas Simpson, for his excellent assistance in language editing. 
 
Kathryn Manning, for her guidance and teaching on statistical analysis.  
 
Dr. Clinton van der Westhuizen, Dr. Azhar Seedat, Dr. Mariette Graham and Dr. Max Rath 
for their contribution in data collection.  
 
Dr. Charle André Viljoen, for his unwavering support, encouragement and mentorship 
throughout the entire project.  
 
Prof Mpiko Ntsekhe, for his experienced mentorship and guidance in every aspect of this 
project. 
 
 
Contributions 
 
Marthinus Coenraad de Villiers developed study protocol, collected and analysed data and 
wrote the manuscript.  
 
Charle André Viljoen and Mpiko Ntsekhe contributed to study design, data analysis and 
reviewing and editing manuscript.  
 
Kathryn Manning contributed to data analysis.  
 
Clinton van der Westhuizen, Azhar Seedat, Max Rath and Mariette Graham contributed to 
data collection. 
  
 6 
Abbreviations 
 
 
CHF – Congestive Heart Failure 
IE – Infective Endocarditis 
IV – Intravenous 
IVDU – Intravenous Drug Use 
IQR – Inter Quartile Range 
OR – Odds Ratio 
RHD – Rheumatic Heart Disease 
SAMJ – South African Medical Journal 
  
 7 
 
Chapter 1: Accepted for publication (SAMJ) manuscript 
 
The changing landscape of infective endocarditis in South 
Africa 
 
 
M C de Villiers,1 MB ChB; C A Viljoen,2 MB ChB, MMed, FCP (SA); K Manning,1  BSc, PG Dipl 
(Diet), MSc (Med); C van der Westhuizen,1 MB ChB; A Seedat,1 MB ChB; M Rath,1 MB ChB; 
M Graham,1 MB ChB; M Ntsekhe,2 MD, PhD, FACC. 
 
1 Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote 
Schuur Hospital, Cape Town, South Africa. 
2 Division of Cardiology, Department of Medicine, Faculty of Health Sciences, University of 
Cape Town and Groote Schuur Hospital, Cape Town, South Africa. 
 
Corresponding author: M Ntsekhe (mpiko.ntsekhe@uct.ac.za) 
 
Keywords: Endocarditis, Outcomes, Mortality 
 
Word count:  Abstract: 349;  
Manuscript (excluding abstract, tables, references): 2187 
  
 8 
Abstract 
 
Background. Little is known about the current clinical profile and outcomes of patients with 
infective endocarditis (IE) in South Africa. 
   
Methods. We conducted a retrospective review of the records of patients admitted to 
Groote Schuur Hospital between 2009 and 2016 fulfilling universal criteria for definite or 
possible IE, in search of demographic, clinical, microbiological, echocardiographic, treatment 
and outcome information. 
 
Results. 105 patients fulfilled the modified Duke criteria for IE. The median age of the 
cohort was 39 years (IQR 29–51), with a male preponderance (61.9%). The majority of 
patients (72.4%) had left-sided native valve endocarditis, 14% had right-sided disease, and 
13.3% had prosthetic valve endocarditis. A third of the cohort had rheumatic heart disease. 
Although 41.1% of patients with left-sided disease had negative blood cultures, the three 
most common organisms cultured in this subgroup were Staphylococcus aureus (18.9%), 
Streptococcus spp. (16.7%) and Enterococcus spp. (6.7%). Participants with right-sided 
endocarditis were younger (29 years (IQR 27-37)), were predominantly intravenous drug 
users (IVDU; 73.3%) and the majority cultured positive for S. aureus (73.3%) with frequent 
septic pulmonary complications (40.0%). The overall in-hospital mortality was 16.2%, with 
no deaths in the group with right-sided endocarditis. Predictors of death in our patients 
were heart failure (OR 8.16, CI 1.77-37.70; p=0.007) and an age > 45 years (OR 4.73, CI 1.11-
20.14; p=0.036). Valve surgery was associated with a reduction in mortality (OR 0.09, CI 
0.02-0.43; p=0.003). 
 
Conclusions.  Infective endocarditis in a typical teaching tertiary care centre in South Africa 
remains an important clinical problem. In this setting, it continues to affect mainly young 
people with post-inflammatory valve disease and congenital heart disease. IE is associated 
with an in-hospital mortality that remains high. Intravenous drug-associated endocarditis 
caused by S. aureus is an important IE subset, comprising approximately 10% of all cases, a 
fact which was not reported 15 years ago, and culture-negative endocarditis remains highly 
prevalent. Heart failure in IE carries significant risk of death and needs a more intensive 
level of care in hospital. Finally, cardiac surgery was associated with reduced mortality, with 
the largest impact in those patients with heart failure.  
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Background 
 
Despite advances in diagnostic imaging, antimicrobial treatment and cardiac surgery, 
infective endocarditis (IE), as defined by the modified Duke criteria,[1] remains a potentially 
fatal condition with an annual in-hospital mortality rate of approximately 20%.[2,3] 
Observational data from the developed world indicate that the profile of IE has changed 
significantly over the last four decades. Infective endocarditis has become a disease that 
predominantly affects older and/or diabetic patients with infections on degenerative native 
valves or prosthetic valves. Rheumatic heart disease (RHD) has all but disappeared as a 
predisposing risk factor.[4–6] The classic clinical signs of IE are now infrequent, with patients 
often presenting with only fever and/or a heart murmur.[4] Furthermore, endocarditis 
caused by oral organisms (such as Streptococcus viridans) and culture-negative endocarditis, 
have each declined significantly as a proportion of IE in the developed world.[4] Nosocomial 
infections from long-term indwelling catheters and intravenous lines are increasing in 
incidence and Staphylococcus aureus, coagulase negative S. aureus and Enterococcus spp. 
are the dominant organisms.[7] In spite of this evolution in the patient and clinical profile of 
IE, in-hospital mortality, morbidity and complication rates remain high. Specifically, 
congestive cardiac failure (CHF), stroke and intra-cardiac abscesses with conduction 
abnormalities are reported at a frequency of approximately 60%, 30% and 1 to 15%, 
respectively.[8–11]   
 
Besides a recent focus on intravenous (IV) drug use related IE[12], there is little contemporary 
data on IE from South or sub-Saharan Africa, with the most recent information on the 
subject published in 2003.[13] Specifically, there is a dearth of information on patient 
profiles, risk factors, predisposing cardiac conditions, and the spectrum of causative 
microbiological organisms. Furthermore, little is known about the prevalence and predictors 
of complications, the proportion of patients with IE who undergo surgery and the in-hospital 
mortality rates in sub-Saharan Africa. This knowledge is vital for increasing the survival of IE 
patients as well as improving their overall care by optimizing local clinical practice. 
  
This study was therefore conducted to address these gaps in our local knowledge, providing 
a contemporary and descriptive overview of IE in a representative South African tertiary 
centre.   
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Methods 
This was a retrospective review of patient records. Patients older than 17 years with 
complete data who fulfilled the modified Duke criteria for infective endocarditis[14] and were 
commenced on treatment for possible or definite infective endocarditis at Groote Schuur 
Hospital in Cape Town in 2009 to 2016 were included. After approval by the University of 
Cape Town’s Human Research Ethics Committee (HREC Ref: 517/2016), 181 potential cases 
were identified by screening the hospital’s electronic database for all hospital admissions 
and referrals to cardiology. Data collection included the collection of demographic, clinical, 
microbiological, echocardiographic, laboratory and outcome data on all identified cases. 
 
Six independent investigators (MCD, CAV, CV, AS, MR and MG) used a standardized data 
collection form, from where data was entered into REDCap (Research Electronic Data 
Capture, a secure online database manager hosted at the University of Cape Town).  All the 
collected data was verified.  Collected data was exported from the REDCap database to 
Stata software, version 14.1 (Stata Corp, College Station, TX), for statistical analysis.  
Descriptive statistics were used to summarize demographic, clinical and microbiological 
variables.  Univariable and multivariable logistic regression was used to determine the 
association between clinically relevant variables and in-patient mortality in patients with 
left-sided IE. Variables were selected a priori and were excluded if data was sparse. Those 
considered for regression analysis were age, sex, comorbidities (including HIV status), serum 
creatinine, white cell count, organism cultured, echocardiographic complications, clinical 
complications and valve replacement surgery performed. Variables were retained in 
multivariable model if the p-value was <0.25 or if an association has been demonstrated in 
previous studies.[15,16] Unadjusted and adjusted odds ratios (OR) were presented with a 95% 
CI. 
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Results 
One hundred and five cases were included in the study (figure 1), with 64.8% (68) and 35.8% 
(37) of patients fulfilling the modified Duke criteria for definite and possible IE respectively. 
In all cases, the responsible clinicians felt it appropriate to commence treatment for 
endocarditis. There was a steady increase in the number of cases seen over the period from 
2009 to 2016, with a peak in 2014 (Supplementary file 1). 
 
The median age of this cohort was 39 years (IQR 29 – 51), with a slight male preponderance 
(61.9%).  The majority of patients had left-sided native valve endocarditis (72.4%) while the 
remainder was evenly split between prosthetic valve endocarditis (PVE, 13.3%) and right-
sided endocarditis (14.3%).   
 
The most common underlying cardiac conditions were RHD (34.3%), mechanical or tissue 
prosthetic valves (13.3%; most of whom had had valve surgery for RHD) and congenital 
heart disease (10.5%). Five patients (4.7%) had a prior history of infective endocarditis and 
one patient had device-associated endocarditis (permanent pacemaker).  Amongst those 
who were tested for HIV (87/105 patients), 23.0% were seropositive. Ten patients (9.5%) 
had diabetes mellitus, while other comorbidities such as chronic kidney disease, chronic 
liver disease and cancer were uncommon (3 patients respectively).  One patient had a 
permanent intravenous (IV) port. A detailed description of the clinical characteristics, special 
investigations and laboratory results can be found in table 1. The most frequent presenting 
signs and symptoms were: fever (63.8%), dyspnoea (61.0%), a temperature > 38.5°C (58.1%) 
and weight loss (24.8%).  Most patients (85.7%) had a new or changed murmur on clinical 
examination. More than a quarter (27.6%) had an acute neurological deficit and 18.1% were 
noted to have splinter haemorrhages (Table 2). 
 
All patients had a transthoracic echocardiogram. Where vegetations were detected, the 
mitral (52.9%) and aortic valve (37.6%) were the most frequently affected. Two-thirds 
(68.4%) of those with aortic valve involvement had severe aortic regurgitation, whereas 
54.1% of those with mitral involvement and 36.4% of those with tricuspid involvement had 
severe regurgitation. 
 
The median number of blood cultures done per patient was 3 (IQR 2.5-4.5). Blood cultures 
were persistently positive after 48 hours in 21.0% of patients in this study (13.2% of left-
sided native endocarditis, 42.9% of prosthetic valve endocarditis and 40.0% of right-sided 
endocarditis; p = 0.006). Based on the attending clinician’s evaluation, the most frequent 
sources of infection were thought to be the skin (66.7%), oral cavity (25.9%) and 
gastrointestinal tract (7.9%).  Of patients with left-sided disease, 41.1% had negative blood 
cultures (fig 2a), and the three most common organisms cultured in this subgroup were 
Staphylococcus aureus (18.9%), Streptococcus spp. (16.7% (S. viridans 10.0%, other 6.7%)) 
and Enterococcus spp. (6.7%). 
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Right-sided disease was different to left-sided disease: Those patients with tricuspid and 
pulmonary valve endocarditis were younger (median age 29.1; IQR 27-37) and had a greater 
male predominance (73.3%); IV drug use was a common risk behaviour (73.3%); and S. 
aureus was the most common organism cultured (73.3%), while 13.3% were culture 
negative (fig 2b).  
 
In-hospital course and outcome 
 
Heart failure was the most common in-hospital complication (42.9%), followed by embolic 
complications (36.1%), acute kidney injury (21.9%) and pneumonia (8.6%).  In-hospital 
mortality was observed only in those with left-sided native and prosthetic valve endocarditis 
and was found to be 18.9% in that subgroup.  Heart failure (adjusted OR 8.16, CI 1.77-37.7; 
p=0.007) and age greater than 45 years (adjusted OR 4.73, 1.11-20.14; p=0.036) were 
significantly associated with an increased in-hospital mortality in this study, however data 
sparsity reduced the precision of these estimates.  HIV, diabetes and infection with S. aureus 
did not appear to influence mortality.  The most common complications for right-sided 
disease were septic pulmonary emboli (40.0%) and acute kidney injury (40.0%). 
 
All patients were treated with antibiotics and 44 (42.3%) underwent valve surgery.  Heart 
failure was the most common indication for surgery (66.7%, p=0.001).  Surgery was 
associated with a reduced risk of death (OR 0.09, CI 0.02-0.43; p=0.003).  Only one patient 
with right-sided endocarditis underwent surgery, i.e. tricuspid valve repair due to severe 
tricuspid regurgitation. 
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Discussion 
We have presented a retrospective review of the hospital records of patients admitted to a 
South African urban tertiary referral centre with a diagnosis of infective endocarditis.  The 
study, which covered the period between 2009 and 2016, is the first of its kind since the 
early 2000s and describes the demographic, clinical and microbiological profile of patients 
with the disease, discusses treatment strategies and provides information about the in-
hospital outcomes and their predictors.  
The main findings of this study demonstrate that: IE in urban South Africa remains a disease 
of relatively young people (median age 39yrs) with rheumatic or congenital heart disease 
(44.8%); culture-negative endocarditis remains a prevalent problem; the proportion of IE 
due to community-acquired S. aureus appears to be growing; and that there is evidence that 
IVDU-associated right-sided endocarditis is now an important problem. Furthermore, we 
found that heart failure was the most common complication of IE, was the most important 
predictor of death and was the main reason patients are referred for cardiac surgery, an 
intervention which was associated with reduced mortality rates.  Finally, HIV, diabetes, 
alcohol use and chronic kidney disease were not important predictors of a poor outcome.  
 
Although no major conclusions can be made from a retrospective review, or from 
comparisons with other studies, it is interesting to compare our findings with data from 
recent international registries[4,17–20] and a similar but older South African study.[13] When 
compared with our findings, these registries suggest that there are major differences in the 
age profile (>70yrs vs <40yrs), clinical profile (degenerative valve disease vs RHD) and 
microbiological profile of the studied IE patients, with apparently fewer cases of culture-
negative and oral organism-related IE seen in the developed world.  
 
Additionally, in comparison to findings from the South African study,[13] the main observed 
differences revolved around the microbiological profile, proportion of IVDU-associated 
right-sided disease and the prevalence of underlying congenital heart disease.  
Whereas in 2003, community-associated S. aureus was noted infrequently, it was found in 
26% of our overall cohort and was the dominant cause of infection in participants with 
IVDU-associated IE. This is in line with a recently published study from Johannesburg which 
found S. aureus to be present in 61% of recreational drug users who developed IE.[12]  The 
same study reported a higher burden of right sided endocarditis at their centre. This could 
possibly be explained by recent data on drug abuse in South Africa which showed higher 
rates of IV drug use in Gauteng than in the Western Cape.[21] On the other hand, viridans 
group streptococci., which were previously dominant, may be diminishing in frequency. The 
high rate of culture-negative IE in our cohort was in line with the previous study and other 
middle- and low-income country data, as demonstrated in a systematic review by Njuguna 
et al.[22]  High rates of the empiric administration of antibiotics prior to blood culture 
collection is often provided as the main reason for high culture-negative IE rates.  In those 
patients with culture-negative IE in our study, 24.8% of patients received antibiotics prior to 
blood culture collection. Culture negative rates are significantly lower in higher income 
countries (10%).[4] 
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Mortality in our cohort (16.2%) was lower than what has previously been reported in other 
middle- and low-income countries (19-46%).[22] A possible explanation for this relatively 
lower than expected mortality was the liberal use of cardiac surgery for those with 
international guideline-based recommendations, such as heart failure.[23] Approximately 
48% of participants with left-sided IE underwent surgery, a figure which was much higher 
than that reported in other low- and middle-income country registries, where about 15% 
receive valve replacement for the same indication.[22,24] 
 
To the best of our knowledge, this is the largest cohort of IE patients in sub-Saharan Africa 
to date and provides important information and insight into the disease in a South African 
context. There are a number of important limitations of this study, including: that it was a 
single-centre, retrospective study; that the number of participants was relatively small; that 
the subgroup sizes were relatively small and unequal; that it is likely that not all patients 
with IE over the given period of interest were captured; and that some patient records may 
have been incomplete and their ICD-9 and ICD-10 information may not have always been 
accurate. As a result of these and other limitations inherent in the design and conduct of 
such a study, caution needs to be taken with the conclusions one  draws as well as with the 
generalizability of the findings.  
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Conclusions 
 
Infective endocarditis in a typical teaching tertiary care centre in South Africa remains an 
important clinical problem. In this setting, it continues to affect mainly young people with 
post-inflammatory valve disease and congenital disease and is associated with an in-hospital 
mortality that is quite high at almost 20%. Intravenous drug-associated endocarditis caused 
by S. aureus is an important IE subset, comprising approximately 10% of all cases, a fact 
which was not reported 15 years ago, and culture-negative endocarditis remains highly 
prevalent. Heart failure in IE carries significant risk of death and needs a more intensive 
level of care in hospital. Finally, cardiac surgery which reduced mortality and it was most 
impactful in those patients with heart failure. These findings suggest that prospective 
cohorts of IE are needed to keep track of changing trends and profiles in order to provide 
clinicians with more robust information to inform their clinical practice and thereby improve 
patient outcomes.  
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Table 1. Demographic, comorbidities, clinical characteristics and mortality of  
patients with left- and right-sided infective endocarditis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations. LVEF, Left ventricular ejection fraction. IQR, Interquartile range. 
 
 
 
Total 
n = 105 
n, (%) 
Left-sided disease 
n = 90 
n, (%) 
Right-sided 
disease 
n = 15 
n, (%) 
Sex - Male 65 (61.9) 54 (60.0) 11 (73.3) 
Age (median, IQR) 39 (29-51) 42.7 (31-53) 29.1 (27-37) 
Congenital heart disease 11 (10.5) 9 (10.0) 2 (13.3) 
RHD 36 (34.3) 36 (40.0) 0 (0.0) 
Previous IE 5 (4.8) 5 (5.6) 0 (0.0) 
Prosthetic valves 14 (13.3) 14 (15.6) 0 (0.0) 
None 31 (29.5) 20 (22.2) 11 (73.3) 
HIV 20/87 (23.0) 20/75 (26.6) 0/12 (0.0) 
IV drug use 15 (14.2) 4 (4.5) 11 (73.3) 
Diabetes Mellitus 10 (9.5) 9 (10.0) 1 (6.7) 
Ethanol use 23 (21.9) 23 (21.9) 0 (0.0) 
Native valve IE 91 (86.7) 76 (84.4) 15 (100.0) 
Prosthetic valve IE 14 (13.3) 14 (15.6) 0 (0.0) 
Duke criteria definite 68 (64.8) 53 (58.9) 15 (100.0) 
Echocardiography 
LVEF (%, IQR) 60 (53-66) 59.5 (53-65) 64 (58-70.5) 
Vegetations present 85 (81.0) 71 (78.9) 14 (93.3) 
    Aortic regurgitation 39 (37.1) 38 (42.2) 1 (6.7) 
    Mitral regurgitation 62 (59.1) 60 (66.7) 2 (13.3) 
    Pulmonary regurgitation 9 (8.6) 8 (8.9) 1 (6.7) 
    Tricuspid regurgitation 34 (32.4) 23 (21.9) 11 (73.3) 
Laboratory values 
    WCC (median, IQR) 12.7 (8.3-15.7) 11.5 (7.7-15.4) 14.95 (13.8-18.5) 
    HB (median, IQR) 10.1 (8.5-11.4) 10.3 (8.8-11.4) 9.15 (7-11.6) 
    Creatinine (median, IQR) 89.5 (67-120) 87 (67-110) 121.5 (62-209) 
Diuretic use 62/100 (59.1) 58/86 (64.5) 4/14 (28.6) 
Valvular surgery performed 44 (42.3) 43 (47.8) 1 (6.7) 
In-patient mortality 17 (16.2) 17 (18.9) 0 (0.0) 
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Table 2. Presenting signs and symptoms of patients with left- and right-sided  
infective endocarditis. 
 
 
Total 
n = 105 
n, (%) 
Left-sided disease 
n = 90 
n, (%) 
Right-sided disease 
n = 15 
n, (%) 
    Fever 67 (63.8) 54 (60) 13 (86.7) 
    Dyspnoea 64 (61.0) 57 (61.5) 7 (46.7) 
    Poor appetite 13 (12.4) 12 (13.3) 1 (6.7) 
    Weight loss 26 (24.8) 22 (24.4) 4 (26.7) 
    Neurological deficit 29 (27.6) 28 (31.1) 1 (6.7) 
    Arthralgia 11 (10.5) 8 (8.9) 3 (20.0) 
    Temperature >38.50C 61 (58.1) 51 (56.7) 10 (66.7) 
    Clubbing 32 (30.5) 28 (31.1) 4 (26.7) 
    New or changed murmur 90 (85.7) 79 (87.8) 11 (73.3) 
    Slinter haemorrhages 19 (18.1) 17 (18.9) 2 (13.3) 
    Haematuria on urine test 
strip 44/64 (68.8) * 35/54 (64.8) 9/10 (90.0) 
 
* data missing on 41 patients 
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Table 3. Complications of patients with infective endocarditis.    
 
Complication 
Total 
n = 105 
n, (%) 
Heart failure 45 (42.9) 
Embolic  38 (36.1) 
     Ischaemic stroke 15 (14.3) 
     Mycotic aneurysm 8 (7.6) 
     Septic pulmonary emboli 6 (5.7) 
     Pulmonary infarct 2 (1.9) 
     Splenic infarct 2 (1.9) 
     Cerebral abscess 2 (1.9) 
     Intracranial haemorrhage 3 (2.9) 
Acute kidney injury 23 (21.9) 
Pneumonia 9 (8.6) 
Septic shock 7 (6.7) 
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Table 4. Univariable and multivariable logistic regression analysis of clinically relevant risk 
factors associated with in-patient mortality in patients with left-sided endocarditis 
 
Abbreviations. OR, odds ratios 
Note: Analysis was restricted to patients with left sided IE as risk profiles differ between 
right- and left-sided IE.  There was insufficient data to conduct similar analysis in right sided 
cohort. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Univariable  
regression analysis 
 
 
Multivariable 
regression analysis 
 
 
Unadjusted OR (95% CI) 
 
p value 
 
Adjusted OR (95% CI) 
 
p value 
Age >45 3.73 (1.26-11.09) 0.018 4.73 (1.11-20.14) 0.036 
Diabetes Mellitus 2.39 (0.53-10.73) 0.225 0.85 (0.12-6.15) 0.870 
Staphylococcus Aureus 1.42 (0.40-5.06) 0.589 2.04 (0.41-10.23) 0.386 
Heart Failure 1.83 (0.63-5.34) 0.269 8.16 (1.77-37.70) 0.007 
Valvular Surgery Performed 0.18 (0.05-0.67) 0.011 0.09 (0.02-0.43) 0.001 
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Background and Rationale 
 
Infective endocarditis (IE), as defined by the modified Duke criteria, (1)  
is a potentially fatal condition. (2,3) In the developed world, the classic clinical 
signs of IE are becoming less common, with patients often only presenting with 
fever and/or heart murmur. (3)   Over and above the diagnostic challenges and 
difficulties, IE remains a difficult condition to manage. (4) Observational data from 
the developed world indicates that the profile of IE has changed significantly over 
the last four decades. It is now a disease which affects predominantly geriatric or 
diabetic patients with degenerative (70%) or prosthetic valves (30%) with 
rheumatic heart disease all but disappearing as a predisposing risk factor. 
Nosocomial infections from long term indwelling catheters and intravenous lines 
are increasing in incidence with staph aureus, coagulase negative staph and 
enterococcus becoming the dominant organisms while infections with traditional 
oral organisms have declined significantly. Congestive cardiac failure, stroke, 
intra-cardiac abscess, conduction abnormalities remain major complications of IE.  
Congestive cardiac failure is the most common indication for early cardiac surgery, 
which is the therapeutic strategy of choice in 50% of patients. (5) Despite this 
evolution in profile, IE carries a significant in-hospital mortality of between 15% 
and 30%, which has changed little over the past four decades. (4,6–8)   
 
There is little contemporary data available on IE from  South or sub-Saharan Africa 
(9). Specifically, there is sparse information about the patient profiles, patient 
related risk factors, the spectrum of heart disease, the spectrum of 
microbiological organisms, complications and their predictors, the proportion of 
patients with IE who undergo surgery, and in hospital mortality rate of the 
condition. This knowledge is vital for improving the health care of patients, the 
clinical practice of care-givers and improving the overall outcomes and survival of 
patients. 
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Purpose of the study 
 
• Aim of study 
 
The aim of this retrospective review of the records is to provide a 
contemporary descriptive overview of infective endocarditis as experienced 
in a large referral hospital in sub-Saharan Africa  
  
• Objectives: 
• Describe the patient profile including demographics and risk factors  
• Describe the spectrum of predisposing structural heart disease  
• Describe the proportion of those who meet criteria for definite, probable 
and possible IE amongst those treated for IE 
• Describe the microbiological spectrum  
• Determine the complications rates with a focus on: 
o Cardiac failure 
o Heart block and intracardiac abscesses 
o Neurological complication (mycotic aneurysms, meningitis, 
strokes) 
o Acute kidney injury  
o Peripheral emboli 
• Proportion of patients treated with Cardiac Surgery 
o Determine the predictors of surgery  
• The in-hospital mortality rate  
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Methodology 
Study design 
 
This study will be a retrospective review of the medical records  of patients 
diagnosed and treated as infective endocarditis at  Groote Schuur Hospital 
between 2007 and 2016.  The analysis will be done by doing a folder review of 
medical and surgical notes, prescription charts and reports of special 
investigations.  
 
Characteristics of the study population 
Inclusion criteria 
This study aims to include all adult patients (>17years) admitted to Groote Schuur 
Hospital for treatment of infective endocarditis between 2007 and 2016. 
 
Exclusion criterial 
Patients to be excluded from this study: 
o Patients with incomplete or missing clinical records 
 
Study methods and procedures for data collection  
Patients who meet the inclusion criteria for the study will be identified through 
the following sources: 
 
1. ECCR (Electronic Continuity of Care Records) – electronic database of discharge 
summaries at Groote Schuur Hospital.  We will use keyword searches, i.e. 
infective endocarditis, and the ICD-10 code, to identify patients, dating back to 
2012 
2. Clinicom system – ICD 10 code (I33.0) will be used to search for patients  
3. Database created by SSM project 77, “Retrospective analysis of the spectrum of 
disease seen during Cardiology consultations at GSH” (HREC ref no 348/2016) 
4. Handwritten discharge summaries from the department of Medicine, dating 
back to 2007 
5. The record of in-patients referrals to Cardiology, kept in E17 Cardiac Clinic 
6. Cardiothoracic “filemaker” internal database for patients who have undergone 
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surgery 
7. Death notification document as obtained trough A5 death administration 
8. Microbiology lab records of patients with blood cultures or PCR positive for 
organisms typically associated with infective endocarditis 
9. The internal records of the Division of Cardiology 
10. Patient folders from records department of Groote Schuur Hospital 
11. Relevant data pertaining to the patients from 
a. NHLS laboratory online results 
b. PACS radiography system 
c. Echocardiography data from records in the echo department in ward E17 
(paper based and via centricity 
 
Sample size 
We anticipate that there are at least 15 cases of IE per year, thus will acquire 150 
patient records. 
 
A paper based data collection sheet will be used to collate data from the above 
sources.  An example of the data collection sheet is included as Appendix 1.   
 
Data will be entered as categorical or nominal values.  The data collection sheet 
will be electronically uploaded to RedCap, from where data extraction will be 
done to Microsoft Excel and SPSS. 
 
To protect patient confidentiality, access to RedCap is password protected and will 
only be able to be accessed by the principal investigator.  Only the principal 
investigator, supervisors and statistician will have access to the data on RedCap, 
MS Excel and SPSS.  Patient confidentiality and anonymity will be maintained by 
identifying patients by their folder numbers.   
The principal investigator will have a team to assist with data collection, 
comprising of: 
 
1. Dr Azhar Seedat 
Persal number: 56383011 
Intern at Groote Schuur Hospital  
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2. Dr Mariette Graham 
Persal number: 22773231 
Intern at Groote Schuur Hospital 
 
3. Dr Max Rath 
Persal number: 56382456 
Intern at Groote Schuur Hospital 
 
4. Dr Clinton van der Westhuizen 
Persal number: 55365914 
Medical Officer in the Department of Medicine at Karl Bremer Hospital 
 
The following data will be collected (see appendix 1 for detail) 
 
1. Demographics, as documented in patient folders and clinical notes 
 
2. Co-morbidities, as documented in clinical notes 
 
3. Heart Valves Infected (native or prosthetic), as documented in clinical notes 
or echocardiogram reports 
 
 
 
 
4. Diagnostic criteria for infective endocarditis 
 
a. Major 
i. Microbiology, as documented in clinical notes or NHLS results 
on DISA or LABTRACK 
ii. Echocardiogram 
b. Minor 
i. Predisposing heart lesions, as per clinical notes 
ii. Clinical presentation, as documented in clinical notes 
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iii. Laboratory investigations, as per NHLS results on DISA or 
LABTRACK 
 
5. Infective source found, as documented in clinical notes 
 
6. Complications, as documented in clinical notes, echocardiogram, 
electrocardiogram and computerised tomography scanning 
 
7. Therapy, as documented on prescription charts 
 
8. Admission to wards or high care units 
 
9. Length of hospital stay 
 
 
Data safety and monitoring 
 
To maintain confidentiality and anonymity, patients will be identified only by their 
hospital numbers in the electronic database used in the study.  Only the data as 
outlined will be collected and analysed. 
 
 
Data analysis 
 
Data will be stored and extracted with a database built in Redcap. Data analysis 
will be performed in Stata (version 13.1, College Station, TX, USA).   
 
Descriptive statistics will be used to present a profile of the total sample namely 
type of IE, risk factors, microbiological characteristics, screening procedures, 
medical complications and surgical interventions.  Continuous variables will be 
described using means ± standard deviations (SD) or medians with interquartile 
range (IQR) depending on their distributions, while categorical variables will be 
expressed as frequencies and percentages. 
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Primary analysis will assess whether there are any associations between profile 
measures, and mortality or morbidity.  Parametric tests (Two-sample T-test for 
continuous or Chi-square test for categorical variables) or non-parametric tests 
(Mann-Whitney U test for continuous or Fisher’s Exact test for categorical 
variables) will be used where appropriate.  Univariate and multivariable logistic 
regression will used to identify risk factors for mortality in patients with IE, and 
provide crude and adjusted odds ratios accordingly.  The incidence rate for death 
will be calculated by the number of cases divided by disease-free person-time of 
observation.  Where applicable, a p<0.05 will be considered statistically significant 
and 95% confidence intervals used to determine the precision of estimates. 
 
Budget 
 
No budget is required. 
 
Timeline 
 
May – July 2016:      Protocol finalization and HREC approval 
August 2016 – July 2017:    Data Collection 
August 2017:      Data Analysis 
September 2017 – February 2018:  Literature review and prepare dissertation 
 
 
Benefits of study 
 
This study aims to  
• Improve understanding of infective endocarditis in our setting 
• Identify areas where our care of infective endocarditis could be improved 
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Ethical considerations 
 
• Risk: 
o This is a low risk study. 
o There is no risk involved for patients participating in this study. 
• Privacy and confidentiality: 
o Patient confidentiality will be maintained at all times. 
• Reimbursement for participation: 
o There will be no reimbursement for participants in this study 
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Appendices to protocol  
 
 
Appendix 1 – Data to be collected 
 
 
1. Demographics 
a. Age 
b. Gender 
 
2. Co-morbidities – As documented in clinical notes 
a. Previous infective endocarditis  
b. Rheumatic heart disease 
c. Congenital heart disease 
d. HIV 
e. Diabetes 
f. Chronic liver disease 
g. Chronic Kidney Disease 
h. Dialysis 
i. Cancer 
 
3. Foreign material – As documented in clinical notes 
a. Dialysis catheters 
b. Intravenous ports 
c. Urethral catheter 
d. Pacemaker 
 
4. Habits – As documented in clinical notes 
a. History of recreational IV drug use 
b. Smoking 
c. Alcohol 
 
5. Heart Valves Infected – As documented in clinical notes 
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a. Native 
b. Tissue prosthesis 
c. Mechanical prosthesis 
d. TAVI 
 
6. Localisation – As documented in clinical notes 
a. Left native 
b. Left prosthesis 
c. Right 
d. Device 
 
7. Clinical Presentation – As documented in clinical notes 
a. Initial symptom 
i. Fever 
ii. Poor apetite 
iii. Weight loss 
iv. SOB (NYHA) 
v. Neurological deficit 
vi. Arthralgia 
 
b. Clinical signs 
i. Fever 
ii. Murmurs 
iii. Clubbing 
iv. Splinter haemorrhages 
v. Janeway lesions 
vi. Osler nodes 
vii. Roth spots 
viii. Splenomegaly 
c. Urinary dipstix 
i. If done 
ii. Presence of hematuria 
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8. Microbiology 
a. Blood cultures 
i. Number done 
ii. Number positive 
iii. Organisms cultured 
 
9. Echocardiogram 
a. Echocardiogram modality (Trans-thoracic or trans-esophageal) 
b. Valve dysfunction – Defined as at least moderate on echo 
i. Aortic 
ii. Mitral 
iii. Pulmonary 
iv. Tricuspid 
c. Vegetation on valve – As documented on echo report 
i. Aortic 
ii. Mitral 
iii. Pulmonary 
iv. Tricuspid 
d. Size of vegetations – Size in cm on echo report 
e. Left ventricular function – Ejection fraction as documented on 
echocardiogram 
f. Complications 
i. Abscess 
ii. Dehiscence of prosthetic valves 
 
 
 
10. ECG findings – As documented in clinical notes 
a. Heart rate 
b. Rhythm 
i. Sinus 
ii. AF 
iii. Heart block 
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c. PR interval 
 
11. Baseline laboratory investigations – Values on presentation to GSH 
a. WCC 
b. Hb 
c. Plt 
d. Creatinine 
e. CRP 
f. ESR 
g. CD4 count 
h. Albumin 
i. Complement C3 C4 
 
12. Infective source found – As documented in clinical notes 
a. Dental 
b. GIT 
c. Skin 
d. Unknown 
e. Other 
 
13. Complications – As documented in clinical notes 
a. Heart failure 
b. Heart block 
c. Prosthetic valve dehiscence 
 
 
d. Embolism 
i. Pulmonary infarcts 
ii. Splenic infarcts 
iii. Cerebral abscess 
iv. Mycotic aneurysms 
v. Septic arthritis 
e. Intracranial haemorrhage  
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f. Septic shock 
g. Renal failure 
h. Death 
 
14. Therapy 
a. Medical 
i. 1. Antibiotics 
a. Which antibiotics used 
b. Duration of treatment 
ii. 2. Diuretics 
iii. 3. Pacing 
a. Temporary 
b. Permanent 
 
b. Surgical 
i. If replacement or repair done 
ii. Duration since diagnosis to surgery 
 
15. Admission 
a. Medical wards 
b. CCU 
c. Cardiothoracic ward 
 
16. Length of hospital stay 
a. Date of admission 
b. Date of discharge / death 
c. Date referred to Cardiology 
d. Date of surgery (if done during admission) 
 
End of appendix 1 
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Data collection tool
Retrospective Analysis infective endocarditis Duke Definite Possible Maj:    Min:
Surname Folder no
First Name Date admission
Date of Birth Date discharge/death
Gender M F Date referred cardio
Co-morbids CLD Prev IE CKD Dialysis Cancer Other:
HIV RHD Diabetes CongHD Pregnancy
Foreign Material Dial Cath IV port Habits Hx IV drug Smoking ETOH
Heart Valves Infected U-Cath Pacemaker Localisation lesion Left Native Left pros
Native Tissue pros Mech pros TAVI Right Device
Clinical presentation Symptoms Fever Poor apetite Weight loss SOB NYHA:
Signs Fever >38.0 Clubbing Neuro def: Arthralgia
Murmur: PrN/Chg/Old Splint haem Janeway Osler Roth Spleen
Urine dip Not done Haem No Haem Bloodcult Organism:
Yes No
Echo Not done TTE TOE Yes No
Valve dysf AR (Mild/Mod/Sev)    PR (Mild/Mod/Sev) Vegetations and size AO MV
None MR (Mild/Mod/Sev)   TR (Mild/Mod/Sev)              mm None PV TV
LVEF: Complications (echo) None
ECG HR: PR: Rhythm: Sinus AF Heart Block Other:
LAB WCC: Hb: Plt: Creat: CRP: ESR: CD4:
HIV: Alb: C3: C4: Infective source Dental GIT
Complications HF Pneumonia Skin Unknown
Pulm infarct Septic
Sept shock Arthritis
Abx + dates
Diuretic Yes No Unknown Pacing None Temp Permanent
Surgery None Repair    AO/MV/PV/TV Admission Medical CCU CT surg
Replace  AO/MV/PV/TV CT ICU O+G
AB Reg Emp Nat Emp Pros Direct Outcome Demise DC Down ref
Investigator Name: Form Complete Incomplete
Signature:
Date Data Collected:
No done:
Yes (Define):
Other:
Abx before BC done
Mycotic AneurysmRenal failure
BC + after 48h No. positive:
Intracranial haemorrhage
Heart Block ( 1 / 2 / 3 )
Date: Other:
5. 6.
1.
2. 3. 4.
Spleen infarct Cerebral abscess
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Ethics and hospital approval 
Signature Removed
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Signature Removed
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Reviewers comments with reply (SAMJ) 
Manuscript revision – reply to reviewer comments 
Reference: SAMJ13888 - The changing landscape of infective endocarditis in South 
Africa 
General impression of this manuscript 
Reviewer #1: Please see comments to the authors- as document attached. 
I think this is a well conducted retrospective review of records of patients admitted with infective endocarditis. 
There is only one paper from this region published more than 10 years ago. The manuscript is well written, the 
tables and figures are relevant and informative, the discussion is comprehensive. I think this manuscript is 
relevant for the South African SAMJ reader as it alerts to the fact that we now see an increasing number of 
right sided infective endocarditis, that despite patients presenting with heart failure the outcome can be 
improved if patients are referred early for surgery. As 24% of the cases received antibiotics prior to having 
blood cultures awareness can be raised take blood cultures earlier. I think this article fits well into a general 
medical journal. 
Thank you for the suggestions and the constructive feedback. 
Reviewer #2: Yes, this article is relevant under South African context. It offers important information on the 
current clinical spectrum of infective endocarditis in a single center and adds to the existing body of knowledge. 
There are similar studies in South Africa. The article is overall reasonably presented. The conclusions are fair 
and are clearly stated. It will sensitize the general practitioner to infective endocarditis and hence improve 
diagnosis and management. It is fit for SAMJ. 
Thank you for reviewing our manuscript and the positive feedback. 
Methods and analysis presented in this manuscript 
Reviewer #1: the research question is well addressed; sample adequate and well described (table 1 and 2). 
We appreciate the positive feedback. 
Reviewer #2: The research question is well stated. The sample for left sided endocarditis is sufficient but not 
for right sided infective endocarditis whereby a larger sample is needed to make any meaningful interpretation 
of results. The methods are well described. Table 1 compares the characteristics of left and right sided 
endocarditis. However, this comparison is statistically questionable due to the significant difference in the 
sample size between the right and left sided endocarditis. 
Thanks for the feedback. We agree that a p value for the differences observed between baseline variables 
between right and left sided endocarditis is meaningless given the numbers and have removed the p values 
from table 1 and table 2.  
 45 
 
Results, Discussion and Conclusions presented in this manuscript 
 
Reviewer #1: Please see comments above and comments to the authors. I would have the one figure as a 
supplementary figure. 
 
Thank you for the comment, see response to comment no.2 on next page.  
Reviewer #2: The population is adequately described. The results are well presented. Except Table one 
comparison as mentioned above the rest are credible. Tables are useful. The pie chart (figure 3b) can be 
deleted as the sample size for right sided endocarditis was small. This information can be written in words 
under results. 
Thank you for pointing out this limitation, as discussed above. As left sided and right sided endocarditis have  
different microbiological profiles, we believe that a visual representation highlighting these differences would be 
beneficial for the reader.  
 
Discussion 
 
Reviewer #1: The results are well discussed. I had just one suggestion for the conclusion of the abstract. 
 
Thank you for this excellent suggestion. We have addressed this in the abstract. 
Reviewer #2: The results are well discussed. A more detailed direct comparison in a table format of the current 
study with the study conducted in 2003 by Koegelenberg CFN would have enhanced the quality of the paper. 
Yes, the limitations are discussed reasonable well. Yes, the relevance of the study is discussed. 
Thank you for the valuable suggestion. The differences in study design and statistical analysis in the 
Koegelenberg study and our study, a direct comparison in a table format leaves incomplete data. However, we 
have described the major differences in the text on page 7:  
 
“…in comparison to findings from the South African study,[13] the main observed differences revolved around 
the microbiological profile, proportion of IVDU-associated right-sided disease and the prevalence of underlying 
congenital heart disease. Whereas in 2003, community-associated S. aureus was noted infrequently, it was 
found in 26% of our overall cohort and was the dominant cause of infection in participants with IVDU-
associated IE.” 
 
 
Conclusion 
 
Reviewer #1: Yes- I just had a minor suggestion how to make the conclusion stronger 
Thank you for the suggestion, please see next page for full reply under comment 1. 
Reviewer #2: Yes, the implications are summarised. The conclusion about IV drug abuse right sided infective 
endocarditis pertaining to this study may not be entirely reflective of the real burden of this disease as this 
group formed minority of the patients. Recommendation for future research is made. 
 
Thank you for this important comment. We agree that the burden of right sided endocarditis in South Africa 
might be greater than what we saw at our centre, however our study shows an increase in right sided IE from 
what was previously shown in the Western Cape. Please also refer to reply of comment no. 6 below. 
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Reviewer #1: Comments to Authors and Editor 
 
The changing landscape to infective endocarditis in South Africa The authors need to be congratulated to a 
well conducted retrospective review of records of patients admitted with infective endocarditis. 
The manuscript is well written, the tables and figures are relevant and informative, the discussion is 
comprehensive. I think this manuscript is relevant for the South African SAMJ reader as it alerts to the fact that 
we now see an increasing number of right sided infective endocarditis, that despite patients presenting with 
heart failure the outcome can be improved if patients are referred early for surgery. As 24% of the cases 
received antibiotics prior to having blood cultures awareness can be raised take blood cultures earlier. 
I have only a few minor suggestions: 
 
1) Conclusion of main manuscript and abstract should be aligned. 48% of patients with left-sided endocarditis 
underwent surgery versus 15% in reports from other LMICs ( Ref 21 & 23). As this clearly impacted on 
(relatively good) outcome I would highlight this more in the abstract. I also suggest highlighting the fact that 
patients presenting with heart failure and infective endocarditis need intensive and high-level care. The OR of 
death is 8.1 in multivariable regression analysis. 
 
Thank you for this important correction. We have aligned the conclusion of the main manuscript with the 
abstract and included above suggestions to highlight the fact that heart failure carries higher mortality and 
needs increased level of hospital care. 
 
See page 2: 
“Infective endocarditis in a typical teaching tertiary care centre in South Africa remains an important clinical 
problem. In this setting, it continues to affect mainly young people with post-inflammatory valve disease and 
congenital disease and is associated with an in-hospital mortality that is quite high at almost 20%. Intravenous 
drug-associated endocarditis caused by S. aureus is an important IE subset, comprising approximately 10% of 
all cases, a fact which was not reported 15 years ago, and culture-negative endocarditis remains highly 
prevalent. Heart failure in IE carries significant risk of death and needs a more intensive level of care in 
hospital. Finally, cardiac surgery which reduced mortality and it was most impactful in those patients with heart 
failure.” 
 
2) Figures: Figure 3 is very nice. If there is not enough space for all the figures and tables I would make figure 2 
supplementary. 
As suggested, we changed figure 2 to supplementary file 1. 
 
See page 5: 
“There was a steady increase in the number of cases seen over the period from 2009 to 2016, with a peak in 
2014 (Supplementary file 1).” 
 
3) Comorbidities: More than 20% of the patients reported enthanol abuse. Was this a predictor of poor 
outcome? I could not find this information in the manuscript. 
 
Thanks for pointing this out. We analysed ethanol use in the univariable regression analysis and did not find it 
to have a statistically significant impact on death amongst those with left sided endocarditis (OR 1.79 with CI 
0.58-5.58, P=0.311). We have added this finding in the discussion section. However, as a limitation of 
retrospective studies, the amount of ethanol use not consistently documented in the majority of patients, and 
we could therefore not use this in our analyses. It would be important to quantify ethanol use in prospective 
studies of IE to have a more accurate analysis of risk of death in the setting of IE. 
 
See page 7: 
“Finally, HIV, diabetes, alcohol use and chronic kidney disease were not important predictors of a poor 
outcome.” 
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Reviewer #2: The study is relevant as it provides contemporary information relating to infective endocarditis in 
a single centre in South Africa and will hopefully stimulate renewed interest in the field in other hospitals in the 
Country. The retrospective nature of the study is an important limitation. 
 
1) Can the Authors provide a more detailed echocardiographic description of these patients echocardiographic 
exam such as ventricular function, dimensions, presence or absence of pericardial effusion, pulmonary 
hypertension?, the mean vegetation size. 
 
Thank you for this comment. As mentioned, retrospective studies are limited by the extent of information that 
can be extracted. We collected the following echocardiographic data: LV function, presence of vegetations and 
associated dysfunction of valve because that was what was noted in all the reports. LV dimensions and 
vegetation size were unfortunately not always documented, and we could therefore not include these values in 
our analysis. It is also important to note that while we felt the additional echo detail may have enhanced the 
descriptive study, we felt that we were still able to meet the main aims and objectives of the study.  
We are conducting a prospective registry where more the requested details are being captured. As suggested, 
we have included the LV systolic function in the descriptive analysis of table 1. 
 
2) Table one provides a comparison of the characteristic of right and left sided endocarditis. However, is this 
comparison valid with such a drastic difference in sample size between the two groups? 
 
We agree that a comparison is not valid given the large differences in size and have removed the p values. We 
do however feel it important to provide the absolute numbers and interquartile ranges  
 
Please see changes to table 1 and table 2 (p-values removed) 
3) A third of the patient were HIV positive, what were their CD4 count and viral load? Should this information 
have not been included in the multivariate analysis? 
 
On univariable regression analysis CD4 count was not associated with death, and was therefore included in 
multivariable regression analysis. Viral load was infrequently measured in this cohort at the time of admission 
for IE and could therefore not be used for any analysis. 
4) How many of the patient with Right sided endocarditis presented with features of pulmonary embolism. One 
of the complication for right sided infective endocarditis was pneumonia, were these not simply cases of septic 
pulmonary emboli misdiagnosed as pneumonia? 
 
The term pneumonia is what was captured from the source documents. However, we agree that septic emboli 
to the lungs are a much more common complication of right sided IE than pneumonia and therefore are likely to 
be the complication which was being describe. The term pneumonia in this context is confusing have therefore 
changed the notation in the text. In the right-sided endocarditis sub-group there were 6 patients who 
complicated with septic pulmonary emboli (documented as pneumonia from source) and the descriptions has 
been changed accordingly in the text and in table 3. 
 
See page 6: 
“The most common complications for right-sided disease were septic pulmonary emboli (40.0%) and acute 
kidney injury (40.0%).” 
“Heart failure was the most common in-hospital complication (42.9%), followed by embolic complications 
(36.1%), acute kidney injury (21.9%) and pneumonia (8.6%).” 
 
Also see table 3 adjusted accordingly.   
5) Which Congenital heart lesion was a predisposing factor for IE in this cohort? 
 
Unfortunately the notes did not always specify the extent of congenital heart disease and we did not include 
this information in the scope of this study as it does not change the aims and objectives originally described.  
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6) The majority of the cases were that of left sided infective endocarditis. Only 11 cases were intravenous drug 
related right sided infective endocarditis over a period of 6 years. This is an interesting finding as it contrasts 
with the current study on IV drug use related infective endocarditis from Chris Hani Baragwanath Hospital, 
where in a period of two years close to 80 patients were diagnosed with IV drug related infective endocarditis ( 
majority had right sided infective endocarditis). Is there an explanation for these contrasting results within the 
same Country? Does this merely reflect the larger number of patients seen at Chris Hani Baragwanath 
Hospital? 
 
That is a very interesting finding indeed.  IV drug use rates are traditionally lower in the Western Cape. In our 
setting there are low rates of IV heroin use but high rates of smoked drug abuse (eg. tik). In contrast, Gauteng 
has much higher IV drug abuse rates. We have included this in our discussion section with reference to recent 
statistical data.  
 
See page 7: 
“…recently published study from Johannesburg which found S. aureus to be present in 61% of recreational 
drug users who developed IE.[12]  The same study reported a higher burden of right sided endocarditis at their 
centre. This could possibly be explained by recent data on drug abuse in South Africa which showed higher 
rates of IV drug use in Gauteng than in the Western Cape.[21]”   
 
7) There was no mortality reported in the right sided infective endocarditis group and it seems they all 
responded to antibiotic therapy except for one patient. What was the reason for surgery in that particular 
patient? Additionally the small sample size in the IV drug related right sided endocarditis group does not reflect 
the true profile and outcomes of this unique group of patients in a resource limited South African setting. 
 
We agree that we have small cohort of right sided endocarditis and that a larger cohort in a prospective study 
would be needed to validate our results. The one patient in the right sided IE group who underwent surgery, 
had a tricuspid valve repair due to severe tricuspid regurgitation.  
 
See page 6 
“Only one patient with right-sided endocarditis underwent surgery, i.e. tricuspid valve repair due to severe 
tricuspid regurgitation.” 
 
8) How many of these patients required additional imaging (in the form of transesophageal echocardiogram, 
PET scan) to make an assessment of infective endocarditis? As this diagnosis can sometimes be challenging. 
At the time of the study duration we did not have access to PET Scanning. All the patients who had surgery 
underwent intra-op TEE prior to their operation but detailed TEE findings were not always available which is 
why we did not include this in the descriptive analysis. 
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